Zacks Investment Research
18 Mar 2026, 22:25 UTC · 34w ago
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
Verdict
Headline leans bullish. We score FDMT +1.00.
Score confirms the headline.
- Headline says
Leans bullish
From its wording — no explicit rating
- Expected · FDMT
+1.00strongly bullish





